World's Best Scientists 2026 revealed!
Joseph A. DiMasi

Joseph A. DiMasi

D-Index & Metrics

Economics and Finance

D-Index
35
Citations
18854
World Ranking
2848
National Ranking
1575

Best Publications

  • The price of innovation: new estimates of drug development costs

    Joseph A. DiMasi;Ronald W. Hansen;Henry G. Grabowski

  • Innovation in the pharmaceutical industry: New estimates of R&D costs

    Joseph A. DiMasi;Henry G. Grabowski;Ronald W. Hansen

  • Cost of innovation in the pharmaceutical industry.

    Joseph A DiMasi;Ronald W Hansen;Henry G Grabowski;Louis Lasagna

  • Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

    J A DiMasi;L Feldman;A Seckler;A Wilson

  • The cost of biopharmaceutical R&D: is biotech different?

    Joseph A. DiMasi;Henry G. Grabowski

  • Risks in new drug development: approval success rates for investigational drugs.

    Joseph A. DiMasi

  • Economics of New Oncology Drug Development

    Joseph A. DiMasi;Henry G. Grabowski

  • Returns on Research and Development for 1990s New Drug Introductions

    Henry Grabowski;John Vernon;Joseph A. DiMasi

  • Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009

    KI Kaitin;JA DiMasi

  • New drug development in the United States from 1963 to 1999.

    Joseph A. DiMasi

  • The value of improving the productivity of the drug development process: faster times and better decisions.

    Joseph A. DiMasi

  • Success rates for new drugs entering clinical testing in the United States

    Joseph A. DiMasi

  • The economics of follow-on drug research and development

    Joseph A. DiMasi;Cherie Paquette

  • Clinical Approval Success Rates for Investigational Cancer Drugs

    J A DiMasi;J M Reichert;L Feldman;A Malins

  • Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project.

    Bennett Levitan;Kenneth Getz;Eric L. Eisenstein;Michelle Goldberg

  • Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

    Joseph A. DiMasi;Ronald W. Hansen;Henry C. Grabowski;Louis Lasagna

  • R&D Costs and Returns by Therapeutic Category

    Joseph A DiMasi;Henry G Grabowski;John M Vernon

  • The economics of follow-on drug research and development: trends in entry rates and the timing of development.

    Joseph A. DiMasi;Cherie Paquette

  • The Cost of Drug Development

    Joseph A DiMasi;Henry G Grabowski;Ronald W Hansen

  • Drug development costs when financial risk is measured using the Fama–French three‐factor model

    John A. Vernon;John A. Vernon;Joseph H. Golec;Joseph A. Dimasi

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Recently Published Articles